AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (890.5 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Publishing Language: Chinese | Open Access

Advances of glucose metabolic reprogramming in tumor drug resistance

Weijing XU, Yang LEI, Zhaoxia WANG ( )
Department of Oncology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China
Show Author Information

Abstract

Tumor drug resistance is the main cause of clinical treatment failure. According to conventional wisdom, resistance is mostly caused by greater drug efflux, accelerated DNA repair, and decreased apoptosis. In recent years, more and more studies have shown that glucose metabolic reprogramming, as a key mechanism for tumor cells to adapt to the unique tumor microenvironment and obtain the advantages of survival and proliferation, also plays a very important role in regulating the process of tumor drug resistance. In addition to providing sustained material and energy supplies for their own rapid growth and proliferation, the abnormally active aerobic glycolysis and pentose phosphate pathway in tumor cells can also affect drug tolerance through pathways like regulating redox homeostasis, enhancing cellular stemness, and reshaping the tumor microenvironment. Additionally, the combination treatments that target glycose metabolic reprogramming combined with anticancer medications have shown progressively greater therapeutic benefits. This article reviews the research progress of glucose metabolic reprogramming in the resistance to various anti-tumor drugs, in order to provide a new breakthrough for the increasingly prominent status quo of tumor cell drug resistance.

CLC number: R730.5 Document code: A Article ID: 1007-4368(2026)06-935-10

References

【1】
【1】
 
 
Journal of Nanjing Medical University (Natural Sciences)
Pages 935-944

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
XU W, LEI Y, WANG Z. Advances of glucose metabolic reprogramming in tumor drug resistance. Journal of Nanjing Medical University (Natural Sciences), 2026, 46(6): 935-944. https://doi.org/10.7655/NYDXBNSN260208

3

Views

0

Downloads

0

Crossref

Received: 11 February 2026
Revised: 19 April 2026
Accepted: 20 April 2026
Published: 15 June 2026
© 2026 Editorial Board of Journal of Nanjing Medical University(Natural Sciences)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).